WISER-P Version 1.0
Research type
Research Study
Full title
WISER-P: Real-world testing of software for measuring bone disease on whole-body MRI in patients with prostate cancer
IRAS ID
315173
Contact name
Dow-Mu Koh
Contact email
Sponsor organisation
The Institute of Cancer Research
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
In advanced prostate cancer, bone disease can occur in 90% of patients. Currently the most widely used scans to find out if cancer has spread to the bones are bone scans and computed tomography (CT). These scans are also used to find out how well treatment for advanced prostate cancer is working. However, it has been shown that whole-body magnetic resonance (MRI) scans are better at assessing response to treatment. By using a special type of MRI scan, called diffusion-weighted imaging, it is possible to get more detailed information about the cancer in bones along with a measurement of how much bone disease there is in the whole skeleton. Despite this, bone scans and CT scans are still widely used across the NHS. This means some patients may be kept on ineffective treatments for longer, leading to poorer disease outcomes.
As the whole-body MRI scan provides detailed information about the cancer in the bones it can take a long time for the radiologist to review and analyse the scan. As part of this study we are also assessing an approved imaging software for whole-body MRI. This software is used to automatically identify and measures bone disease on the whole-body MRI and produce a summary report of the scan results. This software will reduce the amount of time it takes to analyse the whole-body MRI scan. The summary report may also help the oncology doctors when they review the scan results in clinic.
The aim of this study is to find out whether whole-body MRI is better at finding out how well a treatment is working compared with bone and CT scans. This study will also evaluate the whole-body MRI software to find out how useful this is for the doctors when they assess the scans and make decisions about treatment.REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
23/NE/0034
Date of REC Opinion
26 Apr 2023
REC opinion
Further Information Favourable Opinion